Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14

Abstract Introduction Preeclampsia is a serious complication of pregnancy for which there are no efficacious medical treatments. Soluble endoglin is as an anti-angiogenic factor that contributes to the pathogenesis of the disease, however little is known about its molecular regulation in placenta. R...

Full description

Saved in:
Bibliographic Details
Published in:Placenta (Eastbourne) 2015-08, Vol.36 (8), p.932-937
Main Authors: Kaitu'u-Lino, T.J, Hastie, R, Cannon, P, Nguyen, H, Lee, S, Hannan, N.J, Tong, S
Format: Article
Language:English
Subjects:
Antigens, CD - metabolism
E2F1 Transcription Factor - genetics
E2F1 Transcription Factor - metabolism
E2F3 Transcription Factor - genetics
E2F3 Transcription Factor - metabolism
E2Fs
Endoglin
Female
Humans
Internal Medicine
Matrix Metalloproteinase 14 - metabolism
MMP14
Obstetrics and Gynecology
Placenta
Placenta - metabolism
Pre-Eclampsia - genetics
Pre-Eclampsia - metabolism
Preeclampsia
Pregnancy
Receptors, Cell Surface - metabolism
RNA, Small Interfering
Soluble endoglin
Trophoblasts - metabolism
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Preeclampsia is a serious complication of pregnancy for which there are no efficacious medical treatments. Soluble endoglin is as an anti-angiogenic factor that contributes to the pathogenesis of the disease, however little is known about its molecular regulation in placenta. Recent data has demonstrated E2F transcription factors directly regulate MMPs in metastatic disease. Of particular interest was the capacity of E2F1 and E2F3 to up-regulate MMP14, a protease that cleaves and releases soluble endoglin from placenta. The aim of this study was to characterize E2F1 and E2F3 in preeclamptic placenta and assess whether silencing affects soluble endoglin release. Methods E2F1 and E2F3 mRNA, protein expression and localization were assessed in severe early onset preeclamptic and preterm control placentas (delivered
ISSN:0143-4004
1532-3102
DOI:10.1016/j.placenta.2015.06.007